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Gaucher disease (MIM 230800) is the most common storage disorder, caused by hereditary 
deficiency of the lysosomal enzyme of glucocerebrosidase (EC 3.2.1.45). Human glucocerebro-
sidase gene (GBA) is mapped in locus lq21, it is 7.5 kb long and consists of 11 exons. According 
to the data of the largest human gene mutation databases, there are over 300 currently described 
pathogenic variants of GBA gene, most of them are related to the development of Gaucher 
disease. Aim. To identify rearrangements in the GBA gene which conditioned the development 
of Gaucher disease in Ukrainian patients, to compare their spectrum with the variants in patients 
from Slavonic and other European countries and to evaluate genotype-phenotype associations 
for this disease. Methods. The Sanger’s method of direct automated sequencing using ABI 
3130 analyzer (Applied Biosystems). Results. The application of different molecular and 
genetic approaches, including direct sequencing of gene sequence, allowed us to identify 96.8 % 
of mutant alleles in Ukrainian patients with Gaucher disease. Also six new and previously not 
described rearrangements of the GBA gene sequence were identified. Conclusion. The com-
parison of genotypes with clinical form of the disease, identified in patients, demonstrated that 
our results do not contradict the current recognized genotype-phenotype correlations, which 
allow predicting the type and clinical course of the Gaucher disease to some degree.
K e y w o r d s: Gaucher disease, GBA gene.
Introduction
Gaucher disease (MIM 230800) is the most 
common storage disorder, caused by hereditary 
deficiency of the lysosomal enzyme of gluco-
cerebrosidase (EC 3.2.1.45) [1]. In clinical 
terms, Gaucher disease is divided into three 
types depending on the presence and rate of 
neurological manifestation progress [2]. Type 
I Gaucher disease (non-neuronopathic) is the 
most common form, characterized by the ab-
sence of neurological symptoms. The main 
Biomedicine ISSN 1993-6842 (on-line); ISSN 0233-7657 (print) 
Biopolymers and Cell. 2017. Vol. 33. N 1. P 34–47 
doi: http://dx.doi.org/10.7124/bc.000940
35
Analysis of mutations in GBA gene in Ukrainian patients with Gaucher disease 
clinical features of this type of disorder are 
hepatosplenomegaly, pancytopenia and bone 
system abnormalities in rather a wide spectrum 
of severity – from asymptomatic cases to ear-
ly and short manifestation with fatal outcome 
during the first years of life. Type II Gaucher 
disease (acute neuronopathic) is the rarest 
form, the main symptom of which, in addition 
to organomegaly, is early and rapid develop-
ment of severe neurological damage, fatality 
in utero or during infancy. Type III Gaucher 
disease (chronic neuronopathic) is a transient 
form which covers all patients with organo-
megaly and any neurological signs, manifes ted 
after the second year of life.
The human glucocerebrosidase gene (GBA) 
is mapped in locus lq21, it is 7.5 kb long and 
consists of 11 exons. The pseudogene GBAP, 
remarkable for almost 96 % homology to the 
functional gene, is located 16 kb downstream [3]. 
The region, surrounding the GBA gene, contains 
seven other genes and pseudogenes (MTX1, 
MTX1P1, THBS3, MUC1, PROPIN1, COTE1, 
CLK2), which may be involved in the process 
of forming different fusion or recombinant vari-
ants with the GBA gene during the crossing-over 
of this chromosome region [4].
According to the data of the largest human 
gene mutation databases (dbSNP, 1000 
Genomes, HGMD), there are over 300 cur-
rently described pathogenic variants of the 
GBA gene, most of them are related to the 
development of Gaucher disease. As for other 
pathological variants, there are some large 
described insertions/deletions, including the 
deletion of the whole gene [5], as well as a 
considerable number of complex alleles (rec-
alleles), which were formed due to the cross-
ing-over between the functional gene GBA and 
surrounding genetic structures, most frequent-
ly the pseudogene GBAP.
Similar to most hereditary human diseases, 
Gaucher disease is remarkable for considerable 
variability of the frequencies of pathological 
variants of the gene in different populations. 
For instance, the population of Ashkenazi Jews 
is notable for a very high frequency of several 
variants – p.N409S, p.L483P, c.84dupG, 
IVS2(+1)A, RecNciI and RecTL, which to-
gether comprise about 90 % of all mutant al-
leles, with a single replacement p.N409S re-
markable for over 70 % mutant alleles [6]. At 
the same time, these pathological variants in 
non-Jewish patients account for the total of no 
more than 60 % of mutant alleles, and the fre-
quency of replacement p.N409S is in the range 
of 10–50 % depending on the population [5].
There have been studies of the spectrum of 
pathological variants of the GBA gene in patients, 
suffering from Gaucher disease, in many 
European countries [7–15]. This information is 
of great relevance for understanding the origin 
and distribution of the pathological variants of 
this disease as well as for the evaluation of geno-
type-phenotype correlations among patients. 
The aim of our work was to identify patho-
logical variants in the GBA gene which caused 
the development of Gaucher disease in Ukrainian 
patients, to compare their spectrum with the 
variants in the patients from Slavonic and other 
European countries and to evaluate the geno-
type-phenotype associations for this disease.
Materials and Methods
Patients
The genotype was analyzed in 63 patients of 
age from 6 months to 65 years from different 
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regions of Ukraine, who were diagnosed with 
Gaucher disease during the period from 2001 
to 2016, based on the complex of clinical 
(anemia, thrombocytopenia, hepatospleno-
megaly), morphological (Gaucher-like cells 
in the bone marrow biopsy sample) and bio-
chemical (glucocerebrosidase activity defi-
ciency in blood leukocytes) data. As the 
Center of Orphan Diseases of NCSH 
OKHMATDYT of the Ministry of Health of 
Ukraine is the only institution in Ukraine to 
conduct biochemical and molecular-genetic 
testing of Gaucher patients, the group of pa-
tients, examined by us, may be deemed as the 
representative group of Ukrainian population. 
The control group to analyze the pathogenic-
ity of new mutations was formed from the 
blood samples of 50 vo lun teer donors aged 
from 18 to 60 years without any clinical signs 
of lysosomal pathology. All patients (patients’ 
parents) and volunteer donors gave their in-
formed consent to the use of their biomate-
rial for the study. The work has been ap-
proved by the Ethics Committee of SI IGRM 
NAMS of Ukraine.
Screening of major mutations 
Genomic DNA was isolated from peripheral 
blood samples, obtained from EDTA, using 
commercial sets NucleoSpin®Blood (Ma-
cherey-Nagel, Germany) according to the 
manufacturer’s instructions. Missense re-
placements p.N409S and p.L483P were de-
termined by the method of nested PCR and 
subsequent RFLP-analysis as described pre-
viously [16]. The identification of the men-
tioned mutations was conducted using re-
striction endonucleases Xho1 and Msp1 
(MBI Fermentas).
Sequencing of GBA gene
Due to the availability of highly homologous 
pseudogene GBAP, the exon amplification of 
the GBA gene was conducted using the tech-
nology of nested PCR, the first stage of which 
involved the primers, specific for the se-
quence of the functional gene (GenBank 
Accession No. AH006907.2). The sequence 
of primers, which were used for each stage 
of nested PCR, is presented in Table 1. The 
design of primers was independently elabo-
rated using Primer3 software, web-version 
4.0.0 (http://bioinfo.ut.ee/primer3/), the syn-
thesis of primers was ordered in Apply 
Biosystems (USA). 
The first stage of nested PCR envisaged 
obtaining PCR products of 1–4 exons using 
primers 1F and 4R (product 1873 bp), 4–8 
exons using primers 4F and 8R (product 
3777 bp) and 8–11 exons using primers 8F and 
11BR (product 2267 bp). At the second stage 
of nested PCR the fragments of the coding part 
of the GBA gene exons were obtained along 
with 5’- and 3’-non-translating regions and 
intron/exon boundary, using exon-specific 
primers (Table 1). The purification of PCR 
products was conducted using the commercial 
kits NucleoSpin® Gel and PCR Clean-up 
(Macherey-Nagel, Germany) according to the 
manufacturer’s instructions.
The identification of sequence variants of 
the GBA gene was conducted by the method 
of Sanger’s direct automatic sequencing using 
ABI Prism 3130 (Applied Biosystems, USA) 
and BigDye Terminator sequencing kit 
(Applied Biosystems, USA) according to the 
manufacturer’s protocol. All the identified re-
arrangements were confirmed by sequencing 
using both forward- and reverse-primers. The 
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analysis of sequencing results was made using 
programs Chromas and BLAST (http://www.
ncbi.nlm.nih.gov/blast). The electronic data-
bases of known pathogenic variants – dbSNP, 
1000 Genomes, HGMD – were used to char-
acterize the identified rearrangements. The 
analysis of pathogenicity of new variants was 
made using programs PolyPhen2 (http://genet-
ics.bwh.harvard.edu/pph2), SNPs3D (http://
www.snps3d.org) and Provean (http://provean.
jcvi.org/index.php). The description of rear-
rangements in the GBA gene was based on the 
nomenclature, recommended by the Human 
Genome Variation Society (HGVS ver-
sion 15.11, 2016), with the consideration of 
the first 39 amino acids of preprotein [17, 18]. 
To facilitate the comparison of the obtained 
results against the previous publications, the 
first mention of the rearrangement was made 
with the indication of the traditional name in 
brackets, without the consideration of 39 ami-
no acids of preprotein.
Results
Our examination involved 63 patients from 63 
families with confirmed diagnosis of Gaucher 
disease from all the regions of Ukraine, includ-
ing 57 patients, clinically classified as type I 
Gaucher disease (type I GD), 2 patients with 
type II Gaucher disease (type II GD), and 
4 patients with type III Gaucher disease 
(type III GD). The severity degree of the clin-
ical course was determined according to the 
severity index (SSI), suggested by Zimran 
et al. [19]. Table 2 presents the summarized 
clinical and molecular-genetic characteristics 
of the patients, examined by us. Three families 
had two sick siblings each, but only one sibling 
from each family was used in calculations of 
allele frequencies.
A total of 124 out of 126 (98.4 %) mutant 
alleles of the GBA gene were identified. If two 
previously described rearrangements were 
identified in a patient, it was assumed that they 
were in trans-position, which was confirmed 
by the analysis of parents, if available. The 
biological material of parents was unavailable 
Table 1. The design of primers for the GBA gene 
analysis
E
xo
n Type 
of 
primer
The sequence of primer 
(5’-3’)
Tm, 
°C
The 
product 
size, bp
1
F аacagatgagaggaagccaat* 57.9
509
R tctgtgccttgctcaaagag 59.3
2
F gtgggccttgtcctaatgaa 60.3
372
R aacaaaatcctcaccccaaa 62.9
3
F ctcggcctcctaaagtgcta 59.6
552
R gtagcaggcctgaggacatc 59.8
4
F taaccattacacccctcacc* 57.2
507
R caccactgcactcctgtctc* 59.4
5
F aacccaggagcccaagttc 61.4
494
R gttcagccattagcctccac 69.7
6
F gacattttgtcccctgctgt 60.0
533
R ctgatggagtgggcaagatt 60.0
7
F aggctgttctcgaactcctg* 59.6
598
R aggggaatggtgctctagga 61.0
8
F aaaaatctccccaaacctctc* 58.6
585
R atcatggttccccagagttg 59.8
9
F cccacatgtgacccttacct 59.7
354
R gttccaccctgaacaccttc 59.4
10
F agcctctgcaggagttatgg 59.5
477
R agagtgtgatcctgccaagg 60.3
11a
F gctctgctgttgtggtcgt 60.0
498
R gtttccaaagcaagcagcac 61.0
11b
F tgactaaagagggcacagca 59.6
592
R gtcctcacgctcccaagact 61.8
* Primers specific to the sequence of the functional GBA gene 
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Genotype
SS
I 
sc
or
e
1 allele 2 allele
1 I 3 N409S RecNciI 7
2 I 3 del55 L483P+RecG 6
3 I 9 N409S N409S 6
4 I 55 N409S R159W 6
5 I 1 S390I L483P 7
6 I 3 N409S N409S 6
7 I 3 N409S RecC 2 8
8 I 3 ? Rec G 7
9 I 10 N409S L483P 7
10 I 4 R87W RecC 2 7
11 I 3 R202* L483P+RecG 6
12 I 18 N409S N409S 6
13 I 0,5 L483P RecNciI 8
14 I 19 N409S c1324_1326delATT 6
15 I 45 N409S N409S 4
16 I 5 R502C L483P 11
17 I 3 ? Rec G 8
18 I 6 N409S L483P+RecG 6
19 I 7 R87W c901delC 4
20 I 3 N409S W223R 9
21 I 40 F167L Q453R 7
22 I 15 N409S R159W 8
23 I 1 I200S L483P 5
24 I 5 N409S R202* 6
25 I 3 N409S L327P 7
26 I 20 N409S P430A 8
27 I 2 N409S L483P 7
28 I 0,5 R202* G241R 8
29 I 25 N409S L483P 6
30 I 16 N409S RecC 2 6
31 II 0,5 84GG P430A 26 
32 I 12 N409S R535C 7
N
D
is
ea
se
 ty
pe
A
ge
 o
f 
m
an
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st
at
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n,
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ar
s
Genotype
SS
I 
sc
or
e
1 allele 2 allele
33 I 21 N409S R159W 5
34 I 15 N409S L483P 11
35 I 20 N409S L483P 7
36 I 3 G416S G416S 6
37 I 5 N409S L483P 6
38 I 2 N409S RecC 2 5
39 I 6 N409S L483P 6
40 I 15 N409S R159W 5
41 I 10 N409S L483P 7
42 I 3 N409S P217S 8
43 I 15 N409S N131I 6
44 I 3 N409S L483P 5
45 I 45 N409S L483P 5
46 I 5 N409S RecNciI 8
47 I 5 N409S RecNciI 6
48 I 15 N409S RecC 6
49 III 5 R159W+ G241R D448H 26
50 III 1 G416S c999G-A 37
51 I 0,5 V414L RecC 13
52 I 6 N409S L483P 6
53 I 6 N409S L483P 13
54 III 3 N277S Y244* 25
55 I 12 N409S A423D 8
56 I 42 L483P RecC 2 4
57 III 0,5 G416S c203dupC  26
58 I 5 N409S N409S 6
59 I 5 N409S R159W 6
60 I 4 N409S R202* 6
61 II  0,5 G241R A423D  26
62 I 5 G416S G416S 8
63 I 4 N409S L483P 7
Table 2. The genotype and phenotype of Gaucher patients from Ukraine
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for patients No. 4, 15, 21, 45 and 56. New 
variants were identified while obtaining the 
identical results of sequencing two indepen-
dent PCR products and confirmed by the anal-
ysis of parents.
In total, 32 different pathogenic variants of 
the GBA gene were identified. As expected, 
the most common variant was a single nucle-
otide replacement in exon 9 p.N409S 
(N370S) – it was found in 45 out of 124 al-
leles, which amounted to 36.3 %. Five patients 
had this replacement in homozygous state, and 
35 – in heterozygous state.
The second most frequent pathogenic vari-
ant of the GBA gene was the missense replace-
ment in exon 10 p.L483P (L444P), it was 
identified as an individual mutation in 18 al-
leles out of 124, which amounted to 14.5 %. 
This replacement was not identified in homo-
zygous state in any case. Three other patients 
had the p.L483P replacement as part of the 
most common recombinant allele RecNciI, 
which is the result of the conversion of a frag-
ment of exon 10 of the functional gene and a 
pseudogene, and which, in addition to replace-
ment p.L483p, also carries two replacements 
p.A495P (A456P) and p.V499V (V460V) in 
cis-position, remarkable for the pseudogene 
sequence. Additionally, it was established that 
three patients had replacement p.L483P in cis-
position with single nucleotide replacements 
c.*92G>A and c.*102T>C, localized in 3’-non-
translating region (3’UTR) of the GBA gene. 
These replacements were also notable for the 
sequence of pseudogene GBAP, thus, there is 
high probability of these patients to have the 
recombination between a gene and a pseudo-
gene in the site of intron 10 – 3’UTR, de-
scribed as RecG allele [5].
The third most frequent variant (6 out of 
124 alleles, 4.8 %) was found to be a missense 
replacement in exon 5 p.R159W (R120W), 
which was identified in six patients: in five – in 
the compound with p.N409S, and in one pa-
tient with type III GD in the compound with 
a missense replacement in exon 6 p.G241R 
(G202R). The same number of alleles (6 out 
of 124, 4.8 %) had a missense replacement in 
exon 9 p.G416S (G377S), which was identified 
in four patients: two had it in a homozygous 
state and two – in the compound with another 
single nucleotide rearrangement.
Additionally, our studies identified previ-
ously described missense replacement p.G241R 
(G202R) – in three alleles (2.4 %), missense 
replacements p.R87W (R48W) and p.A423D 
(A384D) – in two alleles each (1.6 % each), 
missense replacements p.I200S (I161S), p.P217S 
(P178S), p.N227S (N188S), p.W223R (W184R), 
p.L327P (L288P), p.Q453R (Q414R), p.D448H 
(D409H), p.V414L (V375L), p.R502C (R463C) 
and p.R535C (R496C) – in one allele each 
(0.8 % each). It was established that four alleles 
(3.2 %) had a nonsense replacement in exon 6 
p.R202* (R163*) in a heterozygous state. 
Other single nucleotide rearrangements, identi-
fied in single cases, were the duplications of 
c.84dupG and c.203dupC, as well as a three-
nucleotide deletion without any shift in the read-
ing frame c.1324_1326delATT and deletion 
c.1265_1319del55 in exon 9.
It was observed that there was rather a high 
prevalence of recombinant alleles among our 
examined patients with the involvement of the 
functional gene GBA and pseudogene GBAP. 
For instance, in addition to the abovementioned 
seven patients with alleles RecNciI and RecG, 
five patients with a complex of six replace-
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ments of pseudogene origin in cis-position in 
exon 6 (p.W223R, p.N227R, p.V230G, 
p.S235P, p.G241R, p.F252I) were identified, 
which may correspond to the described recom-
binant allele RecC with the conversion of a site 
between intron 5 and exon 7 (g.4179_5042con) 
[5]. It was found that two more patients had 
cis-position of the abovementioned six replace-
ments of pseudogene origin in exon 6 and re-
placements p.R159W in exon 5. This combina-
tion may correspond to the described recombi-
nant allele RecC5a with the conversion of a 
site between intron 4 and exon 6 
(g.3941_4430con) [5]. Furthermore, two pa-
tients had the single nucleotide replacements 
c.*92G>A and c.*102T>C, localized in 3’-non-
translating region (3’UTR) of the GBA gene. 
These replacements were also notable for the 
sequence of pseudogene GBAP, thus, there is 
high probability of these patients to have the 
recombination between a gene and a pseudo-
gene in the site of intron 11 – 3’UTR [5]. 
Therefore, the total frequency of recombinant 
alleles was 12.9 %. Notably, the final confirma-
tion of the availability and localizations of 
recombinant alleles requires additional studies.
Six pathogenic rearrangements, which have 
not been previously described, are identified 
in the GBA gene – four missense replacements: 
p.N131I in exon 4, p.F167L in exon 5, p.S390I 
in exon 8 and p.P430A in exon 9; a nonsense 
replacement p.Y244* in exon 6 and a single 
nucleotide deletion c.901delC in exon 7. The 
pathogenicity of the identified rearrangements 
was confirmed in silico using programs 
PolyPhen2, SNPs3D and Provean (Table 3). 
None of the mentioned rearrangements was 
found in the database of 1000 Genomes or in 
50 samples of donor blood, examined by us. 
The paternal analysis demonstrated that re-
placements p.S390I and p.Y244* were inher-
ited by probands from fathers, whereas rear-
rangements p.N131I and c.901delC were in-
herited by probands from mothers. The pater-
nal analysis of rearrangements p.F167L and 
p.P430A was not conducted due to the unavail-
ability of the parental biological material of 
the probands. 
Unfortunately, genotypes of two patients 
(patients 8 and 17) are yet to be determined 
completely. It was identified that patient 8 had 
a previously non-described missense replace-
ment p.P94S in exon 3 of the GBA gene, which 
was evaluated as a polymorphic variant during 
the pathogenicity check (Table 4). However, 
we have no possibility to detect the second 
pathogenic alleles in these patients due to a 
lack of material.
Table 3. The analysis of pathogenicity of new mutations in the GBA gene
Rearrangements Score
Conclusion
protein cDNA PolyPhen21 SNPs3D2 Provean3
p.P94S c.402C>T 0.001 1.86 -0.555 benign
p.N131I c.514A>T 1.000 -1.07 -7.134 deleterious
p.F167L c.621T>C 0.990 -2.36 -5.350 deleterious
p.S390I c.1291G>T 0.997 0.21 -2.800 deleterious
p.P430A c.1410C>G 1.000 -2.82 -7.516 deleterious
1 ΔPSIC ≤ 0,5 – benign; 2 SVM score > 0,5 – benign; 3 Provean score > -2,5 – benign.
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Discussion
Our examination of 63 independent 
Ukrainian patients suffering from Gaucher 
disease identified a total of 32 pathogenic rear-
rangements: 22 one nucleotide substitutions, 
2 of which were nonsense replacements, 2 du-
plications, 3 deletions, 1 splicing mutation and 
4 recombinant rearrangements.
Replacement p.N409S is known to belong 
to so called “mild” variants of the gene and is 
almost not found in patients with neurological 
disorders [5]. In the group of Ukrainian pa-
tients replacement p.N409S was also found 
only in patients with type I GD – 41 of them 
carried this replacement in at least one allele, 
which amounted to 71.9 % of all the patients 
with type I GD (Table 4). Moreover, the data, 
obtained by us, confirm the conclusions of 
other researchers on the mitigating impact of 
replacement p.N409S [6]. For instance, the 
availability of this replacement in patients 24 
and 60, regardless of the availability of zero-
mutation p.R202* in another allele, condi-
tioned type I (non-neuronopathic) clinical 
course of medium severity (Table 2). Three 
patients, who had the identified recombinant 
alleles in the compound with replacement p.
N409S which impairs the structure and func-
D
is
ea
se
 ty
pe
Genotype 
Number of 
genotypes/
total number 
of investigated 
patients
(frequences)
I
p.N409S/p.N409S 5/63 (7.9 %)
p.N409S/p.L483P 13/63 (20.6 %)
p.N409S/p.R159W 5/63 (7.9 %)
p.N409S/RecNciI 3/63(4.8 %)
p.N409S/RecC5a 3/63 (4.8 %)
p.N409S/p.R202* 2/63 (3.2 %)
p.N409S/p.A423D 1/63 (1.6 %)
p.N409S/c.1324_1326delATT 1/63 (1.6 %)
p.N409S/p.L327P 1/63 (1.6 %)
p.N409S/p.N131I 1/63 (1.6 %)
p.N409S/p.P217S 1/63 (1.6 %)
p.N409S/p.W223R 1/63 (1.6 %)
p.N409S/p.P430A 1/63 (1.6 %)
p.N409S/p.R535C 1/63 (1.6 %)
p.N409S/RecC 1/63 (1.6 %)
p.N409S/p.L483P+RecG 1/63 (1.6 %)
p.L483P/p.I200S 1/63 (1.6 %)
p.L483P/RecC5a 1/63 (1.6 %)
D
is
ea
se
 ty
pe
Genotype 
Number of 
genotypes/
total number 
of investigated 
patients
(frequences)
I
p.L483P/p.R502C 1/63 (1.6 %)
p.L483P/p.S390I 1/63 (1.6 %)
del55/p.L483P+RecG 1/63 (1.6 %)
p.F167L/p.Q453R 1/63 (1.6 %)
p.G416S/p.G416S 2/63 (3.2 %)
p.R202*/p.L483P+RecG 1/63 (1.6 %)
p.R202*/p.G241R 1/63 (1.6 %)
p.R87W/RecC5а 1/63 (1.6 %)
p.R87W/c.901delC 1/63 (1.6 %)
p.V414L/RecC 1/63 (1.6 %)
p.L483P/RecNciI 1/63 (1.6 %)
RecG/? 2/63 (3.2 %)
II
c.84dupG/p.P430A 1/63 (1.6 %)
p.G241R/p.A423D 1/63 (1.6 %)
III
p.D448H/[p.R159W+p.G241R] 1/63 (1.6 %)
p.G416S/c.999G-A 1/63 (1.6 %)
p.N227S/p.Y244* 1/63 (1.6 %)
p.G416S/c203dupC 1/63 (1.6 %)
Table 4. The genotype frequencies in Gaucher patients from Ukraine
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tion of the GBA gene considerably, underwent 
also a protective impact of the mentioned re-
placement, which conditioned the development 
of type I (non-neuronopathic) Gaucher disease. 
Similar to most populations, replacement 
p.L483P was ranked the second most frequent 
among our patients – 14.5 % (18/124) alleles 
contained this replacement as an individual 
mutation, and 5.6 % more (7/124) – as a con-
stituent of recombinant alleles of distal regions 
of the GBA gene. Traditionally, the replacement 
p.L483P is classified as “severe”, it is often 
associated with the availability of neurological 
disorders in patients, especially in homozygous 
state [5]. No homozygote p.L483P/p.L483P 
was identified in the Ukrainian patients. 17 out 
of 18 carriers of replacement p.L483P, as an 
individual mutation, had type I (non-neurono-
pathic) Gaucher disease i.e. they had no neu-
rological disorders. The severity of this replace-
ment in 13 of them was mitigated by replace-
ment p.N409S in the second allele, in two – by 
the presence of missense replacements p.I200S 
and p.R502C, also remarkable just for non-
neuronopathic type of the disease [5]. One 
patient had replacement p.L483P, identified in 
the compound with RecC5a allele which was 
described predominantly for patients with 
type I Gaucher disease [5, 15]. 
Two homozygous carriers of replacement 
p.G416S were identified among the examined 
patients, both had type I (non-neuronopathic) 
Gaucher disease, which is in agreement with 
the data of other authors about “mild” nature 
of this replacement [20]. In two more patients, 
this variant was identified in the compound 
with another single nucleotide rearrangement – 
one had cytosine duplication in exon 3 of the 
gene (c.203dupC) which conditions the shift 
in the reading frame, and another had the re-
placement of guanine for adenine in the last 
triplet of exon 7, which does not result in the 
amino acid replacement, but impairs the splic-
ing site. Therefore, both rearrangements are 
“severe” by their phenotypic manifestation. It 
is noteworthy that there was no mitigating ef-
fect from “mild” replacement p.G416S on the 
impact of “severe” rearrangement in both pa-
tients who had type III (chronic neuronopa thic) 
Gaucher disease (patients 50 and 57).
Replacement p.R159W is rather common 
for European populations and is usually char-
acterized as “mild” by its phenotypic manifes-
tation [5]. Among the Ukrainian patients this 
variant was identified in 5 patients with type I 
(non-neuronopathic) Gaucher disease in the 
compound with p.N409S and in one patient 
with type III chronic neuronopathic disease 
(patient 49) in the composition of a complex 
allele [p.R159W+p.G241R] and replacement 
p.D448H in the second allele.
While analyzing the phenotype of patients 
with identified recombinant alleles in the GBA 
gene, it should be noted that genotype-pheno-
type correlation in them is ambiguous. On the 
one hand, it was predictable that all patients 
with genotype p.N409S/RecNciI would have 
type I (non-neuronopathic) Gaucher disease. 
A patient with genotype p.L483P/RecNciI (pa-
tient 13) was notable for early manifestation 
and severe clinical course of the disease, which 
conditioned the fatal outcome after a hemor-
rhage, resistant to treatment, at the age of four, 
regardless of conducted enzyme-replacement 
therapy. The absence of neurological symp-
toms in this patient at diagnostics was the 
reason why this case was classified as type I 
(non-neuronopathic) Gaucher disease. 
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However, the “severity” of both mutations and 
early death allow for an assumption that there 
was no sufficient time for manifestation of the 
neurological symptoms in this patient], thus, 
this case may be considered to be type III 
(chronic neuronopathic) Gaucher disease.
Most described cases of the recombinant 
alleles, involving exons 5–7 of the GBA gene 
(RecC and RecC5a), were observed in the 
patients with no neurological disorders that 
was also demonstrated by us. It is notable the 
identification of genotype p.V414L/RecC in 
the patient with early severe clinical course of 
Gaucher disease without any neurological dis-
orders but with hepatic gaucheroma and fatal 
outcome at the age of 6 (patient 51). Taking 
into consideration the published data about the 
clinical course in the patients, homozygous by 
the missense replacement p.V414L, this vari-
ant should be related to “mild” ones by its 
phenotypic manifestation [21]. Therefore, in 
combination with allele RecC, which is also 
mainly observed in the patients with type I 
Gaucher disease, it could be expected that the 
patient 51 has either mild or medium degree 
of clinical course severity. Such contradiction 
requires detailed study to identify the genetic, 
epigenetic, and environmental factors, impact-
ing the phenotypic manifestation of a specific 
genotype.
The results of genotyping other patients 
with neuronopathic types of Gaucher disease 
are in some agreement with the published data. 
Both mutations, identified in the patient 61 
with type II acute neuronopathic disease (gen-
otype p.G241R/p.A423D), described before, 
are remarkable for neuronopathic forms of 
Gaucher disease [22]. The duplication of gua-
nine c.84dupG in exon 2 of the GBA gene, 
identified in a patient with type II (acute neu-
ronopathic) Gaucher disease, was also de-
scribed as a “severe” form according to its 
phenotypic manifestation and is notable for 
neuronopathic forms of the disease. As seen 
from the published data, the phenotypic man-
ifestation of missense replacement p.N227S 
depends on the rearrangement in the second 
allele. The combination of this variant with 
“mild” mutations, such as p.N409S, leads to 
the development of type I Gaucher disease, 
whereas the combination with “severe” muta-
tions, such as Rec-alleles or p.L483P, leads to 
the occurrence of neuronopathic types of the 
disease [5]. Therefore, the nonsense replace-
ment p.Y244*, identified in the compound with 
p.N227S in patient 54, conditioned the deve-
lop ment of type III (chronic neuronopathic) 
Gaucher disease. 
The analysis in silico of new rearrange-
ments in the GBA gene, described by us, 
demonstrated that nonsense replacement 
p.Y244* and missense replacement p.P430A 
might impair the structure and function of the 
gene product the most. The nonsense replace-
ment p.Y244* is responsible for it due to the 
occurrence of a stop-codon in exon 6 and, as 
a result, the formation of a shortened gene 
product, which lost over half of amino acid 
residues and, first and foremost, the active 
site of the enzyme (E379) [23]. The effect of 
missense replacement p.P430A is due to the 
fact that amino acid residue P430 is localized 
in the loop, contacting with β8-strand of the 
first domain TIM barrel in GBA molecule. 
This loop is localized on the upper surface of 
the active site and contacts the substrate mol-
ecule, which makes any replacements in this 
region critical for normal functioning of the 
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active site of the enzyme [24]. Notably, in 
1998 Cormand et al. described another re-
placement of proline 430 – p.P430L in two 
patients with type I Gaucher disease [25]. 
However, in both patients this replacement 
was in the compound with p.N409S, which, 
taking into consideration the mitigating nature 
of this variant, made it impossible to evaluate 
the correlation of replacement p.P430L and 
the patients’ phenotype. Replacement p.
P430A was identified by us in two patients 
– in the patient 26 with type I Gaucher dis-
ease, conditioned by the presence of replace-
ment p.N409S in the second allele, and in the 
patient 31 with type II Gaucher disease, with 
the duplication c.84dupG in the second allele. 
The development of severe acute neurono-
pathic form of the disease in patient 31 (gen-
otype p.P430A/c.84dupG) confirms that the 
replacement of proline 430 is a zero-mutation, 
conditioning a considerable loss in the enzy-
matic activity of glucocerebrosidase.
It is probable that missense replacement 
p.F167L might also impact the functional ac-
tivity of GBA. Phenylalanine 167 is one of 
seven aromatic amino acids, forming a chain 
on one side of the active site pocket of a GBA 
molecule and is involved into the substrate 
recognition [27]. Leucine is not an aromatic 
amino acid, thus the replacement of phenyl-
alanine with leucine leads to the impairment 
in the aromatic chain structure and therefore 
to the impairment of spatial organization of 
the active site pocket of the enzyme, which 
may have negative impact on the catalytic 
activity of glucocerebrosidase. Unfortunately, 
we were unable to evaluate phenotype-geno-
type association of this replacement because 
it was identified in the compound with “mild” 
replacement p.Q453R, which conditioned type 
I Gaucher disease in the patient 21.
Replacements p.N131I and p.S390I, de-
scribed by us, influence amino acid residues, 
localized in domain III, the catalytic domain 
of GBA molecule, but do not participate di-
rectly in the recognition and binding of the 
substrate or activator of saposin C [23, 24]. 
This is the most likely factor, conditioning the 
“mild” impact of conformational changes in 
GBA molecule, caused by these replacements, 
on its catalytic activity. This is also confirmed 
by the clinical data of the patients, described 
by us, – replacement p.N131I in the compound 
with p.N409S led to the development of type 
I Gaucher disease with late manifestation (pa-
tient 43, the first symptoms were identified at 
the age of 15), and replacement p.S390I miti-
gated the impact of “severe” replacement p.
L483P in patient 5 and caused the development 
of type I Gaucher disease, albeit of medium 
severity with early manifestation (first symp-
toms at the age of 1 year), but without neuro-
logical disorders.
Therefore, the application of different mo-
lecular and genetic approaches, including di-
rect gene sequencing, allowed us to identify 
96.8 % of mutant alleles in Ukrainian patients 
with Gaucher disease. Also six new and previ-
ously not described rearrangements of the GBA 
gene sequence were identified. The comparison 
of genotypes with clinical form of the disease, 
identified in patients, demonstrated that at 
present there are recognized genotype-pheno-
type correlations for this disease, which allow 
predicting the type and clinical course of the 
disease to some degree. In most patients, de-
scribed by us, the combination of genotype 
and phenotype corresponded to the data of 
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numerous previous studies. The information 
about clinical signs of the disease in patients 
with new, previously not described mutations, 
allowed us to complement current information 
about genotype-phenotype correlations for 
Gaucher disease. However remarkably, there 
is considerable heterogeneity in the clinical 
course of the disease even among people with 
a similar genotype. This depends on different 
factors, influencing the realization of genetic 
information in a certain individual – the avail-
ability of complex alleles, the influence of 
adjacent or modifying genes, the impact of 
environmental factors, etc. These factors im-
pact the possibilities of the clinical prognosis 
and require additional studies.
Therefore, the determination of molecular 
and genetic nature of a disease in a specific 
patient is the mandatory information, which 
allows confirming the diagnosis, predicting the 
clinical course of the disease and envisaging 
the response to specific therapy.
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Аналіз мутацій в гені GBA у пацієнтів 
з хворобою Гоше в Україні
Н. В. Ольхович, А. М. Недобой, Н. О. Пічкур, 
Н. Г. Горовенко
Хвороба Гоше (MIM 230800) є найбільш поширеним 
захворюванням накопичення, яке спричинене спадко-
вим дефіцитом лізосомного ферменту глюкоцеребро-
зідази (EC 3.2.1.45). Ген глюкоцереброзідази (GBA) 
картований в локусі 1q21, його довжина 7,5 тис.п.н. і 
складається з 11 екзонів. За даними найбільших баз 
даних мутацій генів людини, існує більше 300 описаних 
в даний час патогенних варіантів гена GBA, більшість 
з них пов’язані з розвитком хвороби Гоше. 
Мета. Виявлення перебудов в гені GBA, які зумовили 
розвиток хвороби Гоше у хворих в Україні, порівняння 
їх частоти і спектру з варіантами у пацієнтів з інших 
європейських країн, а також оцінка генотип-фенотип 
асоціації для цього захворювання. Методи. Метод 
прямого автоматичного сиквенування за Сенгером на 
аналізаторі ABI 3130 (Applied Biosystems). Результа­
ти. Застосування різних молекулярних і генетичних 
підходів, включаючи пряме секвенування послідовнос-
ті гена, дозволило нам ідентифікувати 96,8 % мутант-
них алелів у українських пацієнтів з хворобою Гоше. 
Також були виявлені шість нових раніше не описаних 
перебудов послідовності гена GBA. Висновки. 
Порівняння виявлених у пацієнтів генотипів з клініч-
ною формою захворювання показали, що отримані 
результати не суперечать сучасним визнаним генотип-
фенотип кореляціям, які дозволяють певною мірою 
прогнозувати тип і клінічний перебіг хвороби Гоше.
К л юч ов і  с л ов а: хвороба Гоше, ген GBA.
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Анализ мутаций в гене GBA у пациентов 
с болезнью Гоше в Украине
Н. В. Ольхович, А. Н. Недобой, Н. А. Пичкур, 
Н. Г. Горовенко
Болезнь Гоше (MIM 230800) является наиболее рас-
пространенным заболеванием накопления, которое 
вызвано наследственным дефицитом лизосомного 
фермента глюкоцереброзидазы (EC 3.2.1.45). Ген 
глюкоцереброзидазы (GBA) картирован в локусе 
1q21, его длина 7,5 тис.п.н. и состоит из 11 экзонов. 
По данным крупнейших баз данных мутаций генов 
человека, существует более 300 описанных в насто-
ящее время патогенных вариантов гена GBA, боль-
шинство из них связаны с развитием болезни Гоше. 
Цель. Выявление перестроек в гене GBA, которые 
обусловили развитие болезни Гоше у больных в 
Украине, сравнение их частоты и спектра с вариан-
тами у пациентов из других европейских стран, а 
также оценки генотип-фенотип ассоциации для это-
го заболевания. Методы. Метод прямого автомати-
ческого сиквенирования по Сенгеру на анализаторе 
ABI 3130 (Applied Biosystems). Результаты. 
Применение различных молекулярных и генетиче-
ских подходов, включая прямое секвенирование 
последовательности гена, позволило нам идентифи-
цировать 96,8 % мутантных аллелей у украинских 
пациентов с болезнью Гоше. Также были обнаруже-
ны шесть новых ранее не описанных перестроек 
последовательности гена GBA. Выводы. Сравнение 
выявленных у пациентов генотипов с клинической 
формой заболевания показали, что полученные ре-
зультаты не противоречат современным признанным 
генотип-фенотипическим корреляциям, позволяю-
щим в определенной степени прогнозировать тип и 
клиническое течение болезни Гоше.
К л юч е в ы е  с л ов а: болезнь Гоше, ген GBA.
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